DLA Piper advises MidEuropa and Famar on site acquisition from MiP Pharma

DLA Piper has advised private equity investor MidEuropa and its portfolio company FAMAR Group, a European pharmaceutical CDMO (Contract Development and Manufacturing Organization), on the successful completion of the acquisition of a manufacturing facility in Homburg (Saar) from the MiP Pharma Group.

Active in the acquisition was a team from DLA Piper led by Counsel Tatiana Marzoli (Private Equity/M&A, Frankfurt, PICTURED). The team also included Partners Andreas Füchsel (Private Equity/M&A, Frankfurt) and Dr. med. Kokularajah Paheenthararajah (Life Sciences/Patent Litigation, Cologne), Counsel Dr. Thilo Streit (Public Economic Law, Cologne), Senior Counsel Dr. Hans-Peter Löw (Employment Law, Frankfurt), Senior Associates Franziska Weinzierl (Real Estate, Frankfurt) and Aleksandra Lis-Rychlinska (Private Equity/M&A, Munich), as well as Associates Damian Merks (Private Equity/M&A, Frankfurt), Janina Strunk (Regulatory, Cologne), Cora Sprengart (Employment Law, Frankfurt), Nicolas Stilwell (Real Estate, Cologne), Pia Leonarda Riemenschneider (IP, Cologne), Liza Michelsen (Insurance, Cologne), and Monika Marincic (Commercial, Munich).

DLA Piper previously advised MidEuropa on its acquisition of a majority stake in FAMAR from ECM Partners and Metric Capital Partners.

Following completion of the transaction, the facility has been integrated into FAMAR Group’s European manufacturing network, and the site will be further expanded. As part of the acquisition, approximately 100 employees have transferred to FAMAR Group.

FAMAR Group is a European provider of contract development and manufacturing services for pharmaceuticals, employing more than 1,850 people. The acquisition strengthens FAMAR’s position in high-value dosage forms and expands its capabilities in sterile and freeze-dried filling and processing. With the addition of the Homburg site, FAMAR Group will operate a total of seven facilities across Europe.

The MiP Pharma Group distributes prescription generics, primarily antibiotics, as well as over-the-counter medications and medical devices. Its main markets are Germany, Poland, and other Eastern European countries. Since November 2020, MiP Pharma has been part of the portfolio of Berlin-based private equity firm capiton AG.